Literature DB >> 14563891

Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.

Ying Zhang1, Mary Margaret Wade, Angelo Scorpio, Hao Zhang, Zhonghe Sun.   

Abstract

Pyrazinamide is an important sterilizing drug that shortens tuberculosis (TB) therapy. However, the mechanism of action of pyrazinamide is poorly understood because of its unusual properties. Here we show that pyrazinoic acid, the active moiety of pyrazinamide, disrupted membrane energetics and inhibited membrane transport function in Mycobacterium tuberculosis. The preferential activity of pyrazinamide against old non-replicating bacilli correlated with their low membrane potential and the disruption of membrane potential by pyrazinoic acid and acid pH. Inhibitors of membrane energetics increased the antituberculous activity of pyrazinamide. These findings shed new light on the mode of action of pyrazinamide and may help in the design of new drugs that shorten therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563891     DOI: 10.1093/jac/dkg446

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  130 in total

Review 1.  Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis.

Authors:  Jonathan Paul Smith
Journal:  Yale J Biol Med       Date:  2011-12

Review 2.  TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

Authors:  Alberto Matteelli; Anna Cc Carvalho; Kelly E Dooley; Afranio Kritski
Journal:  Future Microbiol       Date:  2010-06       Impact factor: 3.165

3.  Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.

Authors:  Wanliang Shi; Xuelian Zhang; Xin Jiang; Haiming Yuan; Jong Seok Lee; Clifton E Barry; Honghai Wang; Wenhong Zhang; Ying Zhang
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

4.  Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance.

Authors:  Mirko Zimic; Patricia Fuentes; Robert H Gilman; Andrés H Gutiérrez; Daniela Kirwan; Patricia Sheen
Journal:  Tuberculosis (Edinb)       Date:  2011-10-17       Impact factor: 3.131

5.  Crystal structure of the yeast nicotinamidase Pnc1p.

Authors:  Gang Hu; Alexander B Taylor; Lee McAlister-Henn; P John Hart
Journal:  Arch Biochem Biophys       Date:  2007-03-02       Impact factor: 4.013

6.  Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Authors:  Zahoor Ahmad; Mostafa M Fraig; Gregory P Bisson; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

7.  Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.

Authors:  Anthony D Baughn; Jiaoyu Deng; Catherine Vilchèze; Angelica Riestra; John T Welch; William R Jacobs; Oren Zimhony
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

8.  PhoU is a persistence switch involved in persister formation and tolerance to multiple antibiotics and stresses in Escherichia coli.

Authors:  Yongfang Li; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2007-04-09       Impact factor: 5.191

9.  Liver Fatty Acid Binding Protein Deficiency Provokes Oxidative Stress, Inflammation, and Apoptosis-Mediated Hepatotoxicity Induced by Pyrazinamide in Zebrafish Larvae.

Authors:  Yun Zhang; Kechun Liu; Hozeifa M Hassan; Hongli Guo; Pingping Ding; Liwen Han; Qiuxia He; Weiyun Chen; Chung-Der Hsiao; Luyong Zhang; Zhenzhou Jiang
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

10.  Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance.

Authors:  Mirko Zimic; Patricia Sheen; Miguel Quiliano; Andrés Gutierrez; Robert H Gilman
Journal:  Infect Genet Evol       Date:  2009-12-04       Impact factor: 3.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.